glp-1 mayo clinic On the next episode of Aging Forward from Community Med: GLP-1s have made a big impact on the weight loss industry. But what do we need to consider when using them in older age?, Listen to Mayo Clinic Genetic Test Can

Participants experienced an average weight loss of 12-24% over 48 weeks

Munib to create a personalized treatment protocoldetermining injection frequency, dosage, and duration based on your individual needs rather than following a one-size-fits-all approach

They work by mimicking the hormone in the body that regulates appetite and blood sugar

Meghana, T., & Sailaja, A

Survodutide (BI 456906) is a GLP-1R/GCGR dual agonist developed by Boehringer Ingelheim, with outcomes of a phase 2 trial in MASLD and a phase 1 trial in cirrhosis published almost simultaneously with tirzepatide

There's no randomized, controlled trial data on what patients should do specifically if they have RA and if they've lost muscle mass with a GLP-1 medication